HPG1860   Click here for help

GtoPdb Ligand ID: 12910

Synonyms: compound 23 [PMID: 37424079] | HPG-1860
Compound class: Synthetic organic
Comment: HPG1860 is an orally bioavailable nonbile acid farnesoid X receptor (FXR) agonist [1]. It is active in biochemical and cellular FXR assays, it and induces a predicted pharmacodynamic response in vivo. FXR agonism is proposed for the treatment of disease such as nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) where inflammatory and fibrotic processes drive pathological liver damage.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 112.26
Molecular weight 573.49
XLogP 3.76
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@@H]1CN(CCN1C2=NC3=C(C=C(C=C3OC)C(=O)O)S2)CC4=C(C5CC5)ON=C4C6=C(C=CC=C6Cl)Cl
Isomeric SMILES ClC1=CC=CC(Cl)=C1C2=NOC(C3CC3)=C2CN4C[C@@H](C)N(CC4)C5=NC6=C(OC)C=C(C(O)=O)C=C6S5
InChI InChI=1S/C27H26Cl2N4O4S/c1-14-12-32(8-9-33(14)27-30-24-20(36-2)10-16(26(34)35)11-21(24)38-27)13-17-23(31-37-25(17)15-6-7-15)22-18(28)4-3-5-19(22)29/h3-5,10-11,14-15H,6-9,12-13H2,1-2H3,(H,34,35)/t14-/m1/s1
InChI Key JPEHHEUXHNQIIX-CQSZACIVSA-N
No information available.
Summary of Clinical Use Click here for help
HPG1860 is in clinical development.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04480697 Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects Phase 1 Interventional Hepagene (Shanghai) Co., Ltd.
NCT05338034 Phase 2a Study of HPG1860 in Subjects With NASH Phase 2 Interventional Hepagene (Shanghai) Co., Ltd.